Financial Performance - Net sales for the three months ended April 30, 2025, were 940.1million,a1.3927.9 million in the same period of 2024[106]. - Net sales for the nine months ended April 30, 2025, were 2,710.2million,anincreaseof59.3 million, or 2.2%, compared to 2,650.9millionforthesameperiodin2024[122].−NetearningsforthethreemonthsendedApril30,2025,were57.8 million, a decrease of 55.7million,or49.1113.5 million in the same period of 2024[117]. - Net earnings for the nine months ended April 30, 2025, were 252.7million,adecreaseof51.6 million, or 16.9%, compared to 304.3millionin2024[130].−Dilutedearningspershare(EPS)decreasedto0.48 for the three months ended April 30, 2025, down from 0.92intheprioryear,adeclineof48.014.2 million, or 5.3% growth, while the Mobile Solutions segment experienced a decline of 2.6million,or0.41,702.6 million for the nine months ended April 30, 2025, an increase of 27.1million,or1.61,675.5 million in 2024[140]. - Net sales for the Industrial Solutions segment for the three months ended April 30, 2025, were 283.3million,anincreaseof14.2 million, or 5.3%, compared to 269.1millionforthesameperiodin2024[146].−AerospaceandDefensenetsalesincreasedby11.0 million due to ongoing strength in the end markets, while Industrial Filtration Solutions (IFS) net sales increased by 3.2milliondrivenbyreplacementpartsales[147].−NetsalesfortheLifeSciencessegmentforthethreemonthsendedApril30,2025,were74.2 million, an increase of 0.6million,or0.773.6 million for the same period in 2024[160]. Expenses and Costs - Gross margin as a percentage of net sales decreased to 34.2% for the three months ended April 30, 2025, down from 35.6% in the prior year, primarily due to higher manufacturing costs[109]. - Selling, general and administrative expenses decreased by 10.6million,or6.5151.1 million, representing 16.1% of net sales[110]. - Research and development expenses decreased by 3.4million,or14.021.4 million, representing 2.3% of net sales[112]. - Selling, general and administrative expenses were 476.4million,or17.6473.5 million, or 17.9% in 2024[124]. - Research and development expenses decreased by 2.9million,or4.465.3 million, representing 2.4% of net sales for the nine months ended April 30, 2025[126]. Impairment and Tax - The company reported a loss on impairment of intangible assets of 62.0million,or6.662.0 million, or 2.3% of net sales, for the nine months ended April 30, 2025, compared to no expense in 2024[125]. - The effective tax rate increased to 33.6% for the three months ended April 30, 2025, compared to 21.2% in the same period of 2024, primarily due to the impairment loss[115]. - The effective tax rate increased to 26.2% for the nine months ended April 30, 2025, compared to 23.1% in 2024, primarily due to the impairment loss[129]. Cash Flow and Debt - Cash provided by operating activities for the nine months ended April 30, 2025, was 251.0million,adecreaseof115.5 million compared to 366.5millionforthesameperiodin2024[170].−CashusedininvestingactivitiesfortheninemonthsendedApril30,2025,was129.8 million, an increase of 62.0millioncomparedto67.8 million for the same period in 2024[171]. - Total debt as of April 30, 2025, was 638.8million,anincreaseof130.4 million from 508.4millionasofJuly31,2024[177].−CashandcashequivalentsasofApril30,2025,were178.5 million, down from 232.7millionasofJuly31,2024[174].−DividendspaidfortheninemonthsendedApril30,2025,were96.9 million, compared to 90.3millionforthesameperiodin2024[173].ForeignCurrencyandInterestRates−TheestimatedimpactofforeigncurrencytranslationfortheninemonthsendedApril30,2025,resultedinadecreaseinreportednetsalesof10.1 million and a decrease in reported net earnings of 3.4million[187].−TheoverallstrongerU.S.dollarnegativelyimpactedtheCompany′sinternationalnetsalesandnetearningsduetoforeign−denominatedrevenuestranslatingintolessU.S.dollars[187].−AsofApril30,2025,thetotalnotionalamountofforeigncurrencyforwardcontractsdesignatedashedgeswas32.4 million, while those not designated as hedges amounted to 194.3million[189].−ThetotalnotionalamountofnetinvestmenthedgesasofApril30,2025,was€80million,or88.8 million, with maturity dates ranging from 2027 to 2029[190]. - Assuming a hypothetical 0.5 percentage point increase in short-term interest rates, interest expense would have increased approximately $1.7 million in the nine months ended April 30, 2025[192].